Last reviewed · How we verify
NCT06715553
Interventional Programs' Impact on Patients' Quality of Life and Functioning
NA trial testing BALANCE Program (Body, Art, Learning, Activities, Nutrition, Creativity, and Education) in Schizophenia Disorder in 86 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2025
Quick facts
| Lead sponsor | Psychiatric Hospital of the Cross |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 86 |
| Start date | 9 August 2024 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Lebanon |
Drugs / interventions tested
- BALANCE Program (Body, Art, Learning, Activities, Nutrition, Creativity, and Education)
Conditions studied
- Schizophenia Disorder — all drugs for Schizophenia Disorder →
- Interventional Study — all drugs for Interventional Study →
Sponsor
Psychiatric Hospital of the Cross
Who can join
Adults 18 to 65, any sex, with Schizophenia Disorder or Interventional Study. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of the study is to investigate the effect of interventional program in improving the quality of life for individuals with chronic schizophrenia The design of the study will be an interventional study - Randomized Control Trial - taking place in the Psychiatric hospital of the Cross Lebanon. Six types of intervention will be done on the patients such as ping-pong, sport exercise, psychoeducation program, nutrition, art therapy and bibliotherapy. A 100 patients adhering to the inclusion and exclusion criteria will be randomized into two groups (50 patients in the intervention group and 50 patients in the control group) - Simple Randomization. A Baseline and follow-up assessments will take place at the beginning of the study and after three months through using Arabic Validated Scales. The scales that be used are the following Positive and negative symptoms scale (PANSS), to determine severity of symptoms in patients. WHO quality of life questionnaire WHOQOL- BREF Arabic version: physical, psychological, social and environmental and EQ-5D scale, to determine quality of life of patients. MOCA scale to determine cognitive function, Rosenberg self-esteem questionnaire, Social functioning questionnaire QFS and Birchwood Insight Scale.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06715553
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Schizophenia Disorder
Currently open trials in the same condition.
- NCT07306468 — Effects of Schizophrenia and Bipolar Disorder on Exercise Capacity, Pulmonary Function, and Quality of Life · recruiting
- NCT06865937 — Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness (R33) · NA · recruiting
- NCT06856161 — A Novel Blood Test as a Biomarker in Mental Health · recruiting
- NCT06831435 — Effectiveness of Digital Cognitive Behavioral Therapy for the Treatment of Depression: a Real-world Study · NA · recruiting
- NCT07453420 — Profiling Vulnerability and Resilience for Mental Illness Following Viral Infections: Translating Epidemiology to Deep-p · active not recruiting
Other Psychiatric Hospital of the Cross trials
Trials by the same sponsor.
- NCT07437365 — Theta- and Alpha-Tuned Meditation for Negative Symptoms in Schizophrenia · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06715553 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Psychiatric Hospital of the Cross
- Last refreshed: 10 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06715553.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing